Improving Platelet Activity for Cerebral Hemorrhage Treatment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury

NCT01810276

Traumatic Head Injury Intracranial Hemmorhage Anti-platelet Therapy

TERMINATED NA

High-Dose Deferoxamine in Intracerebral Hemorrhage

NCT01662895

Intracerebral Hemorrhage

TERMINATED PHASE2

Platelet Transfusion in Acute Intracerebral Hemorrhage

NCT00699621

Intracerebral Hemorrhage

UNKNOWN NA

rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets

NCT00222625

Intracerebral Hemorrhage

UNKNOWN PHASE2

Desmopressin for Bleeding Related to Low Body Temperature

NCT00902057

Hypothermia Induced Impairment of Primary Haemostasis

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intracerebral Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DDAVP

DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes

Group Type EXPERIMENTAL

DDAVP injection (desmopressin acetate)

Intervention Type DRUG

0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DDAVP injection (desmopressin acetate)

0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Spontaneous intracerebral hemorrhage as documented by head CT scan
* Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication

Exclusion Criteria

* International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
* History of von Willebrand disease
* Pregnancy
* Known hypersensitivity to DDAVP or desmopressin
* Active cardiovascular disease or unstable angina
* Hyponatremia or history of hyponatremia
* Current or historical deep venous thrombosis or pulmonary embolism

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No